BSX Stock Cash Flow Statements

Boston Scientific Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Boston Scientific Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30

net income	795,000,000	672,000,000	562,000,000	469,000,000	322,000,000	493,000,000	504,000,000	504,000,000	270,000,000	314,000,000	140,000,000	188,000,000	260,000,000	110,000,000	95,000,000	419,000,000	186,000,000	341,000,000
adjustments to reconcile net income to cash from operating activities
depreciation and amortization	336,000,000	325,000,000	348,000,000	306,000,000	311,000,000	304,000,000	313,000,000	300,000,000	298,000,000	285,000,000	294,000,000	284,000,000	284,000,000	274,000,000	290,000,000	272,000,000	263,000,000	268,000,000
deferred and prepaid income taxes	-90,000,000	41,000,000	-80,000,000	-11,000,000	-10,000,000	31,000,000	73,000,000	-29,000,000	-64,000,000	19,000,000	7,000,000	23,000,000	-18,000,000	-75,000,000	-75,000,000	39,000,000	-87,000,000	-1,000,000
stock-based compensation expense	75,000,000	74,000,000	69,000,000	68,000,000	66,000,000	63,000,000	59,000,000	59,000,000	60,000,000	55,000,000	55,000,000	58,000,000	55,000,000	52,000,000	49,000,000	51,000,000	47,000,000	47,000,000	42,000,000	40,000,000	46,000,000	42,000,000	41,000,000	42,000,000	38,000,000	36,000,000	36,000,000	36,000,000	32,000,000	36,000,000	31,000,000	34,000,000	32,000,000	30,000,000	29,000,000	29,000,000	30,000,000	28,000,000	28,000,000	26,000,000	27,000,000	26,000,000	24,000,000	26,000,000	27,000,000	26,000,000	28,000,000	27,000,000	26,000,000	24,000,000	23,000,000	28,000,000
goodwill and other intangible asset impairment charges			110,000,000	0			0	1,000,000			0	125,000,000
net gain on investments and notes receivable	-219,000,000	28,000,000	19,000,000	14,000,000	44,000,000	2,000,000	11,000,000	13,000,000	4,000,000	31,000,000	-45,000,000	10,000,000	16,000,000	20,000,000	-42,000,000	-186,000,000	15,000,000	-37,000,000
contingent consideration net expense	-5,000,000	5,000,000	-1,000,000	-22,000,000	1,000,000	17,000,000	15,000,000	12,000,000	19,000,000	12,000,000	-33,000,000	20,000,000	36,000,000	12,000,000	-19,000,000	-26,000,000	-85,000,000	-6,000,000
inventory step-up amortization	37,000,000	81,000,000					0	3,000,000			0	7,000,000	8,000,000	17,000,000	19,000,000	7,000,000	0	8,000,000
other	79,000,000	-7,000,000	52,000,000	14,000,000	12,000,000	-4,000,000	40,000,000	10,000,000	25,000,000	-2,000,000	33,000,000	61,000,000	20,000,000	11,000,000	19,000,000	6,000,000	4,000,000	22,000,000
increase in operating assets and liabilities, excluding purchase accounting:
trade accounts receivable	-32,000,000	-107,000,000	-90,000,000	-33,000,000	-114,000,000	-114,000,000	-74,000,000	-3,000,000	-75,000,000	-86,000,000	-44,000,000	-14,000,000	-96,000,000	-66,000,000	-148,000,000	14,000,000	-28,000,000	-117,000,000
inventories	65,000,000	-109,000,000	46,000,000	-55,000,000	-95,000,000	-124,000,000	-59,000,000	-202,000,000	-214,000,000	-185,000,000	-46,000,000	-95,000,000	-72,000,000	-108,000,000	-31,000,000	-215,000,000	15,000,000	-115,000,000
other assets	-31,000,000	-77,000,000	-17,000,000	17,000,000	-71,000,000	-55,000,000	53,000,000	12,000,000	-14,000,000	-41,000,000	89,000,000	-54,000,000	-104,000,000	-140,000,000	11,000,000	55,000,000	-72,000,000	-128,000,000
accounts payable, accrued expenses and other liabilities	231,000,000	-385,000,000	385,000,000	237,000,000	71,000,000	-450,000,000	23,000,000	17,000,000	289,000,000	-211,000,000	335,000,000	-141,000,000	-81,000,000	-368,000,000	133,000,000
cash from operating activities	1,286,000,000	541,000,000	1,456,000,000	1,002,000,000	813,000,000	164,000,000	957,000,000	698,000,000	658,000,000	190,000,000	807,000,000	470,000,000	307,000,000	-58,000,000	478,000,000	465,000,000	643,000,000	284,000,000	673,000,000	643,000,000	269,000,000	-77,000,000	692,000,000	502,000,000	292,000,000	350,000,000	19,000,000	501,000,000	-403,000,000	193,000,000	872,000,000	255,000,000	185,000,000	114,000,000	466,000,000	-31,000,000	421,000,000	116,000,000	329,000,000	408,000,000	60,000,000	-197,000,000	440,000,000	346,000,000	285,000,000	198,000,000	273,000,000	250,000,000	396,000,000	163,000,000	369,000,000	272,000,000
capex	-157,000,000	-187,000,000	-277,000,000	-179,000,000	-155,000,000	-179,000,000	-267,000,000	-190,000,000	-143,000,000	-111,000,000	-212,000,000	-150,000,000	-105,000,000	-121,000,000	0	-107,000,000	-106,000,000	-75,000,000	-159,000,000	-49,000,000	-68,000,000	-100,000,000	-186,000,000	-121,000,000	-91,000,000	-63,000,000	-106,000,000	-76,000,000	-74,000,000	-60,000,000	-79,000,000	-60,000,000	-68,000,000	-112,000,000	-167,000,000	-71,000,000	-78,000,000	-60,000,000	-85,000,000	-70,000,000	-46,000,000	-46,000,000	-79,000,000	-56,000,000	-65,000,000	-59,000,000	-84,000,000	-57,000,000	-51,000,000	-53,000,000	0	-46,000,000
free cash flows	1,129,000,000	354,000,000	1,179,000,000	823,000,000	658,000,000	-15,000,000	690,000,000	508,000,000	515,000,000	79,000,000	595,000,000	320,000,000	202,000,000	-179,000,000	478,000,000	358,000,000	537,000,000	209,000,000	514,000,000	594,000,000	201,000,000	-177,000,000	506,000,000	381,000,000	201,000,000	287,000,000	-87,000,000	425,000,000	-477,000,000	133,000,000	793,000,000	195,000,000	117,000,000	2,000,000	299,000,000	-102,000,000	343,000,000	56,000,000	244,000,000	338,000,000	14,000,000	-243,000,000	361,000,000	290,000,000	220,000,000	139,000,000	189,000,000	193,000,000	345,000,000	110,000,000	369,000,000	226,000,000
investing activities:
purchases of property, plant and equipment and internal use software	-157,000,000	-187,000,000	-277,000,000	-179,000,000	-155,000,000	-179,000,000	-267,000,000	-190,000,000	-143,000,000	-111,000,000	-212,000,000	-150,000,000	-105,000,000	-121,000,000
payments for acquisitions of businesses, net of cash acquired	-1,009,000,000	-239,000,000	-3,418,000,000	-1,127,000,000	-48,000,000	-47,000,000	-793,000,000	0	-643,000,000	-375,000,000	0	-71,000,000	0	-1,471,000,000	-244,000,000	-1,308,000,000	0	-706,000,000	0	0			0	-3,619,000,000	-442,000,000	-321,000,000	-480,000,000	-550,000,000	-409,000,000	-9,000,000	-168,000,000	0			-338,000,000				-92,000,000	-1,579,000,000			1,000,000	-415,000,000	-64,000,000	-8,000,000					-232,000,000	0
payments for investments and acquisitions of certain technologies	-33,000,000	-77,000,000														-21,000,000	-17,000,000	-13,000,000	-16,000,000	-101,000,000	-27,000,000	-2,000,000	-12,000,000	-22,000,000	-87,000,000	-28,000,000	-24,000,000	-36,000,000	-9,000,000	-103,000,000									-264,000,000	0	0	-2,000,000
proceeds for settlements of hedge contracts
cash from investing activities	-1,126,000,000	-500,000,000	-3,704,000,000	-1,427,000,000	-271,000,000	-285,000,000	-1,053,000,000	-197,000,000	-840,000,000	-484,000,000	-183,000,000	-225,000,000	-29,000,000	-1,574,000,000	-461,000,000	-1,207,000,000	0	71,000,000	-147,000,000	-129,000,000	-59,000,000	-76,000,000	-49,000,000	-3,962,000,000	-620,000,000	-410,000,000	-595,000,000	-662,000,000	-491,000,000	-173,000,000	-289,000,000	-102,000,000	-479,000,000	-140,000,000	-532,000,000	-205,000,000	-102,000,000	-48,000,000	-170,000,000	-1,719,000,000	-246,000,000	-51,000,000	-83,000,000	-473,000,000	-124,000,000	-65,000,000	-363,000,000	-73,000,000	-28,000,000	-11,000,000	-273,000,000	-49,000,000
financing activities:
payment of contingent consideration previously established in purchase accounting			0	-97,000,000	0	-34,000,000	0	0	-5,000,000	-34,000,000	0	-52,000,000	-263,000,000	-20,000,000	-1,000,000	0	-3,000,000	-11,000,000
payments for finance leases	-6,000,000	-36,000,000	0	0	0	-25,000,000
payments on short-term borrowings	-500,000,000	-1,083,000,000	0	0	0	-504,000,000					0	0	0	-250,000,000					0	-250,000,000	-2,400,000,000	-300,000,000	0	0	0	-1,000,000,000
proceeds from long-term borrowings, net of debt issuance costs	0	1,558,000,000	0	0	0	2,145,000,000					0	0	-1,000,000	3,271,000,000					0	0			986,000,000	2,000,000,000	0	4,243,000,000													0	749,000,000							0
cash used to net share settle employee equity awards	-5,000,000	-118,000,000	-4,000,000	-3,000,000	-2,000,000	-78,000,000	-2,000,000	-2,000,000	-2,000,000	-50,000,000	-4,000,000	-2,000,000	-1,000,000	-46,000,000	-2,000,000	-1,000,000	-1,000,000	-46,000,000	0	-2,000,000	0	-57,000,000	-1,000,000	-3,000,000	-1,000,000	-60,000,000	-2,000,000	-2,000,000	-2,000,000	-50,000,000	-1,000,000	-2,000,000	-1,000,000	-61,000,000	-5,000,000	-1,000,000	1,000,000	-57,000,000	-4,000,000	0	-1,000,000	-61,000,000	-3,000,000	-1,000,000	0	-47,000,000
proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans	32,000,000	115,000,000		96,000,000	26,000,000	80,000,000		75,000,000	27,000,000	63,000,000		59,000,000	6,000,000	52,000,000		64,000,000	20,000,000	18,000,000		59,000,000
cash from financing activities	-340,000,000	233,000,000	214,000,000	7,000,000	24,000,000	1,569,000,000	15,000,000	16,000,000	43,000,000	-69,000,000	1,000,000	-199,000,000	-344,000,000	-6,000,000	-8,000,000	6,000,000	2,000,000	-95,000,000	-819,000,000	-249,000,000	1,105,000,000	256,000,000	-724,000,000	1,314,000,000	256,000,000	2,127,000,000	425,000,000	151,000,000	726,000,000	130,000,000	-68,000,000	-139,000,000	332,000,000	-15,000,000	28,000,000	34,000,000	-217,000,000	-51,000,000	-191,000,000	761,000,000	846,000,000	-94,000,000	-14,000,000	18,000,000	6,000,000	-160,000,000	-263,000,000	-137,000,000	-106,000,000	-90,000,000	-242,000,000	-243,000,000
effect of foreign exchange rates on cash	2,000,000	39,000,000	-9,000,000	6,000,000	-1,000,000	-7,000,000	4,000,000	-5,000,000			3,000,000	-6,000,000			-1,000,000	-3,000,000	1,000,000	-3,000,000	6,000,000	1,000,000	0	-9,000,000	12,000,000				1,000,000	-4,000,000	-6,000,000	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000	-3,000,000			2,000,000	1,000,000	-3,000,000	1,000,000	-3,000,000	-2,000,000			1,000,000			0	-1,000,000	1,000,000	1,000,000
net increase in cash, cash equivalents, restricted cash and restricted cash equivalents	-179,000,000	314,000,000	-2,044,000,000	-412,000,000	565,000,000	1,441,000,000	-77,000,000	513,000,000	-143,000,000	-363,000,000	629,000,000	39,000,000	-71,000,000	-1,639,000,000	9,000,000	-739,000,000	645,000,000	258,000,000	-287,000,000	266,000,000	1,316,000,000	93,000,000	-69,000,000	-2,147,000,000	-73,000,000	2,067,000,000	-151,000,000	-14,000,000	-174,000,000	151,000,000
cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period	0	606,000,000	0	0	0	1,055,000,000	0	0	0	1,126,000,000	0	0	0	2,168,000,000	0	0	0	1,995,000,000	0	0	0	607,000,000	0	0	0	829,000,000	0	0	0	1,017,000,000
cash, cash equivalents, restricted cash and restricted cash equivalents at end of period	-178,000,000	919,000,000	-2,043,000,000	-413,000,000	566,000,000	2,496,000,000	-77,000,000	512,000,000	-143,000,000	763,000,000	629,000,000	39,000,000	-71,000,000	529,000,000	9,000,000	-739,000,000	645,000,000	2,253,000,000	-287,000,000	266,000,000	1,316,000,000	700,000,000	-69,000,000	-2,147,000,000	-73,000,000	2,896,000,000	-151,000,000	-14,000,000	-174,000,000	1,168,000,000
payments for royalty rights		-10,000,000	0	-11,000,000	0	-15,000,000	0	-16,000,000	0	-34,000,000	0	-36,000,000	0	-39,000,000	0	-43,000,000	0	-42,000,000
net increase in commercial paper		-192,000,000						-41,000,000			0	-155,000,000	-69,000,000	223,000,000					0	0	0	-714,000,000	-588,000,000	-662,000,000	305,000,000	370,000,000	424,000,000	-875,000,000	788,000,000	-316,000,000	-70,000,000	240,000,000
gain on disposal of businesses and assets															-30,000,000
debt extinguishment net charges
investing activities
proceeds from sale of property, plant and equipment			2,000,000	0	0	1,000,000	0	1,000,000	0	3,000,000	2,000,000	1,000,000	1,000,000	8,000,000	4,000,000	3,000,000	3,000,000	4,000,000		2,000,000	1,000,000	3,000,000		3,000,000	0	2,000,000																						0	0	53,000,000
proceeds from disposal of certain businesses and assets											0	0
proceeds from royalty rights			4,000,000	5,000,000	4,000,000	7,000,000	7,000,000	7,000,000	7,000,000	9,000,000	16,000,000	18,000,000	17,000,000	19,000,000	20,000,000	19,000,000	21,000,000	22,000,000	21,000,000	21,000,000	22,000,000	23,000,000
proceeds from settlements of hedge contracts												0				0
financing activities
proceeds from short-term borrowings, net of debt issuance costs			2,000,000																0	0	1,245,000,000	1,000,000,000					0
payments on long-term borrowings and debt extinguishment costs											0	0	0	-3,184,000,000					-260,000,000	0	0	-1,000,000,000	-2,088,000,000	0	0	-1,472,000,000
cash dividends paid on preferred stock							0	0	-14,000,000	-14,000,000	-13,000,000	-14,000,000	-14,000,000	-14,000,000	-13,000,000	-14,000,000	-14,000,000	-14,000,000	-14,000,000
proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans
payments for investments and acquisitions of certain technologies, net of investment proceeds				-125,000,000	-73,000,000	-66,000,000
proceeds from (payments for) investments and acquisitions of certain technologies							0	-16,000,000	-63,000,000	-10,000,000	12,000,000	-22,000,000	1,000,000	-15,000,000
net decrease in commercial paper
debt extinguishment costs											0	0	0	194,000,000
proceeds from (payments for) settlements of hedge contracts								0
payments on borrowings from credit facilities																			0	0	-1,440,000,000	-479,000,000					0	0			0	0	-1,481,000,000	-735,000,000	-240,000,000	-290,000,000	0	-40,000,000	0	-170,000,000			0	-160,000,000	-365,000,000	-285,000,000	-100,000,000	0	0	-240,000,000	-120,000,000	0
proceeds from borrowings on credit facilities																			0	0	77,000,000	1,839,000,000					0	0	499,000,000	70,000,000	0	0	1,140,000,000	1,016,000,000	300,000,000	290,000,000	0	40,000,000	0	170,000,000			0	160,000,000	365,000,000	285,000,000	100,000,000	0	0	240,000,000
net proceeds from issuance of preferred stock in connection with public offering																			0	0
net proceeds from issuance of common stock in connection with public offering																			0	0
payments for repurchase of common stock
foreign exchange (gain) loss														9,000,000	10,000,000	8,000,000	7,000,000	2,000,000
proceeds from divestiture of certain businesses and assets														5,000,000
proceeds from divestiture of certain businesses																							0
proceeds from royalty rights transfer
intangible asset impairment charges																128,000,000
purchases of property, plant and equipment																-107,000,000	-106,000,000	-75,000,000	-159,000,000	-49,000,000	-68,000,000	-100,000,000	-186,000,000	-121,000,000	-91,000,000	-63,000,000	-106,000,000	-76,000,000	-74,000,000	-60,000,000	-79,000,000	-60,000,000	-68,000,000	-112,000,000	-167,000,000	-71,000,000	-78,000,000	-60,000,000	-85,000,000	-70,000,000	-46,000,000	-46,000,000	-79,000,000	-56,000,000	-65,000,000	-59,000,000	-84,000,000	-57,000,000	-51,000,000	-53,000,000
proceeds from sale of investments and disposition of certain assets
proceeds from disposal of businesses																0	0	801,000,000
gain on disposal of businesses																	-2,000,000	-6,000,000
accounts payable and accrued expenses																	197,000,000	-10,000,000
other liabilities																	137,000,000	16,000,000
proceeds from sale of investments																	84,000,000	38,000,000
gain on sale of businesses
proceeds on disposals of property, plant and equipment
payments for settlements of hedge contracts																							95,000,000
proceeds from divestiture																				0
payment of contingent consideration and royalty rights established in purchase accounting																				-42,000,000
supplemental information
fair value of contingent consideration recorded in purchase accounting																							0	-4,000,000	44,000,000	87,000,000	58,000,000	50,000,000							46,000,000				32,000,000	0
non-cash impact of transferred royalty rights																				-21,000,000	-22,000,000	-23,000,000
payment of contingent consideration and royalty rights previously established in purchase accounting																						-76,000,000
proceeds from issuances of shares of common stock																						42,000,000	10,000,000	50,000,000	10,000,000	53,000,000	7,000,000	41,000,000	15,000,000	38,000,000	6,000,000	35,000,000	11,000,000	33,000,000	3,000,000	35,000,000	46,000,000	27,000,000	17,000,000	27,000,000	16,000,000	54,000,000	8,000,000	19,000,000	9,000,000	24,000,000	15,000,000	40,000,000	9,000,000	10,000,000	1,000,000	11,000,000
contingent consideration expense
payment of contingent consideration in excess of amount recognized at acquisition
exchange (gain) loss
increase in operating assets and liabilities, net of acquisitions:
cash (received) paid for income taxes
cash paid for interest
reconciliation to amounts within the consolidated balance sheets:
cash and cash equivalents
restricted cash and restricted cash equivalents included in other current assets
restricted cash equivalents included in other long-term assets
payment of contingent consideration amounts and royalty rights previously established in purchase accounting
payment of contingent consideration amounts previously established in purchase accounting																									-57,000,000	-7,000,000		-11,000,000				-12,000,000	0	-18,000,000
operating activities
payments of contingent consideration previously established in purchase accounting
payments on long-term borrowings																											0	0	0	-602,000,000	0	-400,000,000	-350,000,000	-250,000,000	0	0			-150,000,000	0							0				-1,000,000	0
proceeds from long-term borrowings, net of debt issuance and extinguishment costs																											-2,000,000	0	-1,000,000	990,000,000
payment of contingent consideration in excess of amounts established in purchase accounting
pension termination charges
proceeds from investments and collections of notes receivable
payments of contingent consideration amounts previously established in purchase accounting
net payments for investments, acquisitions of certain technologies and issuances of notes receivable																																-42,000,000
net increase in cash and cash equivalents																																15,000,000	39,000,000	-40,000,000	-41,000,000	-201,000,000	100,000,000	19,000,000	-31,000,000	-553,000,000	661,000,000	-345,000,000	341,000,000	-111,000,000	166,000,000	-26,000,000	-354,000,000	41,000,000	262,000,000	61,000,000	-145,000,000	-19,000,000
cash and cash equivalents at beginning of period																																0	0	196,000,000	0	0	0	319,000,000	0	0	0	587,000,000	0	0	0	217,000,000	0	0	0	207,000,000	0	0
cash and cash equivalents at end of period																																15,000,000	39,000,000	156,000,000	-41,000,000	-201,000,000	100,000,000	338,000,000	-31,000,000	-553,000,000	661,000,000	242,000,000	341,000,000	-111,000,000	166,000,000	191,000,000	-354,000,000	41,000,000	262,000,000	268,000,000	-145,000,000	-19,000,000
payments for investments, acquisitions of certain technologies and issuances of notes receivable																																		-28,000,000
gain on sale of property, plant and equipment
net incomees (gains) on investments and notes receivable
proceeds from business divestitures, net of costs																																											0	0	0	12,000,000	0	0			0
payments for acquisitions of treasury stock																																											0	0	0	-125,000,000	-225,000,000	-75,000,000	-100,000,000	-100,000,000	-100,000,000	-250,000,000
cash paid for income taxes
proceeds from disposal of property, plant and equipment																																				0	-1,000,000	30,000,000
purchases of privately-held securities																																				-54,000,000
purchases of notes receivable																																				-10,000,000	0	-5,000,000				-3,000,000
payment of contingent consideration																																				0	-14,000,000	-21,000,000		-15,000,000	0	-87,000,000		0	-3,000,000	-12,000,000		-92,000,000
purchases of privately held securities																																						-13,000,000		-69,000,000				0	0	-6,000,000		-5,000,000	-4,000,000	-4,000,000
goodwill impairment charges
increase in cash flows from operating assets and liabilities:
proceeds from sales of publicly traded and privately held equity securities and collections of notes receivable																																												0	5,000,000	7,000,000
non-cash operating activities:
property, plant and equipment
proceeds on disposals
acquisitions
divestitures
other investing activity
debt
equity
payments for investments in companies and acquisitions of certain technologies																																												0	10,000,000	-11,000,000		-6,000,000	0	-7,000,000		-17,000,000
purchase of notes receivable																																																-5,000,000
fair value of contingent consideration recorded																																														3,000,000
deferred income taxes
net (gains) losses on investments and notes receivable
contingent consideration income
cash paid (received) for income taxes
purchases of property, plant and equipment, net of proceeds																																																				-46,000,000
proceeds from borrowings on credit facilities, net of debt issuance costs																																																				0
payments relating to prior-period acquisitions

We provide you with 20 years of cash flow statements for Boston Scientific stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Boston Scientific stock. Explore the full financial landscape of Boston Scientific stock with our expertly curated income statements.

The information provided in this report about Boston Scientific stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.